Intensity Therapeutics to work with Merck on its lead prduct combined with Keytruda
Phase 1/2 clinical trial to evaluate Intensity’s INT230-6 in combination with KEYTRUDA® (pembrolizumab) for multiple solid tumor types
Pharmaceuticals, Biotechnology and Life Sciences
Phase 1/2 clinical trial to evaluate Intensity’s INT230-6 in combination with KEYTRUDA® (pembrolizumab) for multiple solid tumor types
Contrad Swiss, a pharmaceutical company focused on breakthrough, innovative products that reframe the world of medicine, announces a new partnership with Dr JO Serrentino.
Leading South Korean biopharmaceutical modernizes trial operations to maintain inspection readiness and have a comprehensive view of study status PLEASANTON,…
— Compassionate use results to be presented at UMDF’s Mitochondrial Medicine 2019 symposium — — Minovia initiates U.S. operations in…
BOSTON–(BUSINESS WIRE)–Decibel Therapeutics, a clinical-stage biotechnology company developing novel therapeutics for hearing loss and balance disorders, today announced the appointment…
DUBLIN–(BUSINESS WIRE)–The “Pyrogen Testing Market – Growth, Trends, and Forecast (2019 – 2024)” report has been added to ResearchAndMarkets.com’s offering.…
Bioasis submitted to the FDA its pre-IND briefing document in support of the xB3-001 program for the treatment of patients with confirmed human epidermal growth factor receptor 2 (“HER2”)-positive (“HER2+”) breast cancer and brain metastases.
TORONTO–(BUSINESS WIRE)–Antibe Therapeutics Inc. (TSXV: ATE, OTCQB: ATBPF): To our shareholders, As we approach the end of Phase 2 development…
CINCINNATI–(BUSINESS WIRE)–Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced that it will report its second quarter 2019 financial results after…
SAN DIEGO–(BUSINESS WIRE)–Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and…